Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai Seeks To Block Dr Reddy’s Over Belviq Plans In India

Executive Summary

Eisai has moved court against Dr Reddy’s for alleged infringement of its patent on Belviq in India. The case is expected to put the spotlight back on prickly IPR issues, including working of patents.

You may also be interested in...



Court Restrains Dr Reddy’s In Indian Belviq Case

An Indian court has granted an interim injunction against Dr Reddy’s in a case concerning the alleged infringement of Eisai’s patent on Belviq. Dr Reddy’s, however, claims that Eisai is a “patent squatter” and expects to appeal against the order.

India’s Emcure Launches First Generic of Eisai's Halaven, Changing Pricing Scenario

Indian drug company Emcure says it is launching the first generic version of Japanese drugmaker Eisai's Halaven which targets metastatic breast cancer and will undercut the branded drug’s price in the country by nearly half.

Interview: Eisai India Unit’s Pivotal Role As Japan Genericizes

Eisai India chief Dr. Sanjit Singh Lamba outlines the competitive edge that the Japanese group’s Indian site offers under the deal with Nichi-Iko; the site has also never “depended” on active pharmaceutical ingredients from China. In a wide-ranging interview with Scrip, Lamba also discusses recent quality compliance initiatives in India.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1133342

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel